title: [The antitumor activity of DPD inhibitory-fluoropyrimidine (DIF) and non-DIF alone or in combination with paclitaxel against orthotopically implanted human breast cancer].
authors.affiliation: Cancer Research Laboratory, Taiho Pharmaceutical Co., Ltd.
authors.forename: Mamoru
authors.initials: M
authors.lastname: Nukatsuka
authors.forename: Akio
authors.initials: A
authors.lastname: Fujioka
authors.forename: Fumio
authors.initials: F
authors.lastname: Nakagawa
authors.forename: Hideyuki
authors.initials: H
authors.lastname: Ohshimo
authors.forename: Kenji
authors.initials: K
authors.lastname: Kitazato
authors.forename: Masakazu
authors.initials: M
authors.lastname: Fukushima
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D042943:Dihydrouracil Dehydrogenase (NADP); D005260:Female; D005467:Floxuridine / Q000008:administration & dosage / Q000494:pharmacology; D006801:Humans; D051379:Mice; D008813:Mice, Inbred ICR; D009368:Neoplasm Transplantation; D010088:Oxidoreductases / Q000037:antagonists & inhibitors*; D017239:Paclitaxel / Q000008:administration & dosage*; D011743:Pyrimidines / Q000494:pharmacology*; D005641:Tegafur / Q000008:administration & dosage / Q000494:pharmacology; D014498:Uracil / Q000008:administration & dosage / Q000494:pharmacology
chemical_list: D000970:Antineoplastic Agents; D011743:Pyrimidines; D005467:Floxuridine; D005641:Tegafur; D014498:Uracil; C029269:5-fluoropyrimidine; D010088:Oxidoreductases; D042943:Dihydrouracil Dehydrogenase (NADP); D017239:Paclitaxel; C025034:doxifluridine